Novel approach based on InVision® liquid biopsy platform predicts response to immune checkpoint inhibitors
October 08, 2019 07:00 ET
|
Inivata
Novel approach based on InVision® liquid biopsy platform predicts response to immune checkpoint inhibitors New peer-reviewed publication outlines an approach that identifies NSCLC patients who...
Inivata to Present New Clinical Data on the Utility of Liquid Biopsy and InVisionFirst®-Lung at World Conference on Lung Cancer 2019
August 29, 2019 07:00 ET
|
Inivata
Inivata to Present New Clinical Data on the Utility of Liquid Biopsy and InVisionFirst®-Lung at World Conference on Lung Cancer 2019 Oral presentation and posters to feature Inivata’s...
Inivata announces launch of clinical trial to evaluate impact of InVisionFirst®-Lung liquid biopsy test on time to appropriate treatment in advanced lung cancer
July 18, 2019 07:00 ET
|
Inivata
Inivata announces launch of clinical trial to evaluate impact of InVisionFirst®-Lung liquid biopsy test on time to appropriate treatment in advanced lung cancer Prospective, interventional study...
Inivata Signs Distribution Agreement with IPS Genomix for InVision® Genomic Tests in the Middle East and Africa
July 16, 2019 07:00 ET
|
Inivata
Inivata Signs Distribution Agreement with IPS Genomix for InVision® Genomic Tests in the Middle East and Africa Research Triangle Park, NC, USA and Cambridge, UK, and Dubai, UAE , July 16, 2019...
Inivata publishes positive clinical validation results and real-world utility for its InVisionFirst®-Lung liquid biopsy test
April 26, 2019 07:00 ET
|
Inivata
Inivata publishes positive clinical validation results and real-world utility for its InVisionFirst®-Lung liquid biopsy test InVisionFirst®-Lung demonstrated excellent concordance with tissue...
Inivata Completes $52.6m (£39.8m) Series B Funding Round
March 28, 2019 07:00 ET
|
Inivata
Inivata Completes $52.6m (£39.8m) Series B Funding Round Funds will accelerate commercialization of InVisionFirstTM-Lung Liquid Biopsy test and the development of the InVision® liquid biopsy...
Inivata Publishes Positive Results of Clinical Validation and Utility Study for InVision® Liquid Biopsy Test
March 07, 2019 07:00 ET
|
Inivata
Inivata Publishes Positive Results of Clinical Validation and Utility Study for InVision® Liquid Biopsy Test Large, real-world, prospective study shows Inivata’s liquid biopsy test is able to...
Inivata Receives Medicare Final Coverage Decision for InVisionFirstTM-Lung Liquid Biopsy Test in Advanced Non-Small Cell Lung Cancer
March 05, 2019 07:00 ET
|
Inivata
Inivata Receives Medicare Final Coverage Decision for InVisionFirstTM-Lung Liquid Biopsy Test in Advanced Non-Small Cell Lung Cancer Final Coverage Supports the Use of InVisionFirst-Lung for Aiding...
Inivata to Present Results of Prospective Clinical Validation Study of its InVisionFirstTM-Lung Liquid Biopsy Test in Advanced Non-Small Cell Lung Cancer (NSCLC) at the World Conference on Lung Cancer
September 24, 2018 07:00 ET
|
Inivata
Inivata to Present Results of Prospective Clinical Validation Study of its InVisionFirstTM-Lung Liquid Biopsy Test in Advanced Non-Small Cell Lung Cancer (NSCLC) at theWorld Conference on Lung...
Inivata Achieves Major Milestone with Draft Medicare Local Coverage Determination (LCD) for InVisionFirst™-Lung Liquid Biopsy Test
September 13, 2018 13:07 ET
|
Inivata
Inivata Achieves Major Milestone with Draft Medicare Local Coverage Determination (LCD) for InVisionFirst™-Lung Liquid Biopsy Test Draft Coverage Supports the Use of InVisionFirst-Lung for Aiding...